The EMA’s Committee for Medicinal Products for Human Use adopted a positive opinion, recommending a change to the terms of the marketing authorization for the medicinal product Calquence. The marketing authorization holder for this medicinal product is AstraZeneca (AZN) AB. The CHMP adopted a new indication to include treatment of adults with previously untreated chronic lymphocytic leukemia in combination with venetoclax.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- Tempus AI Stock (TEM) Surges over 14% in a Day – What’s Next for Investors?
- AI Daily: OpenAI said to forecast revenue topping $125B in 2029
- BTIG says AstraZeneca deal demonstrates value of Tempus AI data AI business
- Tempus AI announces oncology collaboration with AstraZeneca, Pathos AI
- Promising Trial Results and Physician Enthusiasm Bolster AstraZeneca’s Stock Outlook